Cumberland Pharmaceuticals (CPIX) Sets New 12-Month Low Following Analyst Downgrade

Shares of Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) reached a new 52-week low during trading on Friday after B. Riley lowered their price target on the stock from $9.25 to $8.75. B. Riley currently has a buy rating on the stock. Cumberland Pharmaceuticals traded as low as $5.50 and last traded at $5.50, with a volume of 5241 shares trading hands. The stock had previously closed at $5.61.

Separately, ValuEngine upgraded shares of Cumberland Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its stake in Cumberland Pharmaceuticals by 4.5% in the 4th quarter. Renaissance Technologies LLC now owns 330,300 shares of the specialty pharmaceutical company’s stock worth $2,431,000 after purchasing an additional 14,295 shares during the period. Prudential Financial Inc. acquired a new position in Cumberland Pharmaceuticals in the 1st quarter worth $138,000. Finally, Ariel Investments LLC boosted its stake in Cumberland Pharmaceuticals by 28.7% in the 2nd quarter. Ariel Investments LLC now owns 1,305,052 shares of the specialty pharmaceutical company’s stock worth $8,000,000 after purchasing an additional 291,126 shares during the period. 34.52% of the stock is owned by hedge funds and other institutional investors.

The company has a market capitalization of $92.69 million, a price-to-earnings ratio of -79.57 and a beta of 0.65. The company has a current ratio of 4.10, a quick ratio of 3.70 and a debt-to-equity ratio of 0.20.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its earnings results on Tuesday, August 14th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.09. The firm had revenue of $10.16 million during the quarter, compared to analyst estimates of $9.94 million. Cumberland Pharmaceuticals had a negative net margin of 22.65% and a negative return on equity of 4.37%. equities research analysts predict that Cumberland Pharmaceuticals, Inc. will post -0.24 EPS for the current year.

About Cumberland Pharmaceuticals (NASDAQ:CPIX)

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, together with its subsidiaries, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. Its marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for the treatment of chronic and acute constipation; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Ethyol (amifostine) for injection to treat oncology patients; and Totect Injection for the treatment of toxic effects.

Recommended Story: How to Use the New Google Finance Tool

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply